智通财经APP讯，万泰生物(603392.SH)发布公告，近日，公司收到世界卫生组织(以下简称“WHO”)出具的体外诊断预认证(PQ)确认函，公司的HIV尿液自检试剂-人类免疫缺陷病毒 1 型尿液抗体检测试剂盒(胶体金法)(英文名称：HIV SELF TEST BY URINE – Human Immunodeficiency Virus (HIV) Type-I Urine Antibody Diagnostic Kit (Colloidal Gold))已通过WHO 的预认证，被WHO列入体外诊断产品预认证清单。
这是继公司的人类免疫缺陷病毒抗体诊断试剂盒(酶联免疫法)及人类免疫缺陷病毒(HIV 1+2 型)抗体检测试剂盒(胶体金法)通过 WHO PQ 认证后，第三款通过 WHO PQ 认证的 HIV 检测产品，同时是全球首款获得 WHO PQ 的 HIV 抗体尿液自检试剂盒。标志着公司的产品性能及质量管理体系再次获得国际认可。
作为全球首款 HIV 抗体尿液自检试剂盒，获得 WHO PQ 认证意味着公司的HIV 抗体尿液自检试剂盒获得了国际权威认可，可直接参与联合国及全球多边机构的集中采购项目，覆盖更多中低收入国家和地区，将对公司开拓国际市场带来积极影响，有利于进一步提升公司产品的国际竞争力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.